Goldman Sachs’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.7M Buy
1,876,750
+441,023
+31% +$4.84M ﹤0.01% 2554
2025
Q4
$17.8M Sell
1,435,727
-96,607
-6% -$1.28M ﹤0.01% 2501
2025
Q3
$22M Sell
1,532,334
-193,195
-11% -$2.65M ﹤0.01% 2164
2025
Q2
$21.2M Buy
1,725,529
+65,018
+4% +$944K ﹤0.01% 2080
2025
Q1
$36.5M Buy
1,660,511
+35,790
+2% +$842K 0.01% 1464
2024
Q4
$36.8M Buy
1,624,721
+318,203
+24% +$6.95M 0.01% 1557
2024
Q3
$23.7M Buy
1,306,518
+701,397
+116% +$16.3M ﹤0.01% 1911
2024
Q2
$17.6M Buy
605,121
+12,009
+2% +$356K ﹤0.01% 1987
2024
Q1
$21M Sell
593,112
-59,042
-9% -$2.36M ﹤0.01% 1799
2023
Q4
$28.4M Sell
652,154
-31,139
-5% -$1.23M 0.01% 1595
2023
Q3
$26.1M Buy
683,293
+70,105
+11% +$2.95M 0.01% 1579
2023
Q2
$25.2M Sell
613,188
-188,902
-24% -$9.09M 0.01% 1652
2023
Q1
$46M Sell
802,090
-316,288
-28% -$17.8M 0.01% 1123
2022
Q4
$62.7M Buy
1,118,378
+140,707
+14% +$7.16M 0.02% 990
2022
Q3
$41.4M Sell
977,671
-488,541
-33% -$25M 0.01% 1252
2022
Q2
$79.2M Sell
1,466,212
-53,531
-4% -$3.21M 0.02% 830
2022
Q1
$97.7M Buy
1,519,743
+37,025
+2% +$2.44M 0.02% 782
2021
Q4
$99.3M Buy
1,482,718
+629,202
+74% +$42.6M 0.02% 826
2021
Q3
$58.4M Sell
853,516
-27,554
-3% -$1.95M 0.01% 1170
2021
Q2
$60.1M Buy
881,070
+86,991
+11% +$6.15M 0.01% 1105
2021
Q1
$54.9M Buy
794,079
+239,762
+43% +$16.2M 0.01% 1109
2020
Q4
$36M Sell
554,317
-190,774
-26% -$10.3M 0.01% 1386
2020
Q3
$35.2M Buy
745,091
+83,427
+13% +$3.97M 0.01% 1280
2020
Q2
$31.1M Sell
661,664
-324,459
-33% -$15.9M 0.01% 1328
2020
Q1
$44M Buy
986,123
+280,818
+40% +$14.7M 0.02% 958
2019
Q4
$41.1M Buy
705,305
+392,285
+125% +$23.4M 0.01% 1300
2019
Q3
$18.8M Buy
313,020
+12,176
+4% +$725K 0.01% 1830
2019
Q2
$16.8M Buy
300,844
+40,759
+16% +$2.1M ﹤0.01% 1986
2019
Q1
$14.5M Sell
260,085
-42,534
-14% -$2.17M ﹤0.01% 2131
2018
Q4
$13.6M Buy
302,619
+32,061
+12% +$1.76M ﹤0.01% 2116
2018
Q3
$17.8M Sell
270,558
-747,738
-73% -$46.5M ﹤0.01% 2012
2018
Q2
$65.6M Sell
1,018,296
-104,227
-9% -$6.45M 0.02% 1017
2018
Q1
$62.1M Buy
1,122,523
+64,816
+6% +$3.4M 0.02% 1054
2017
Q4
$50.6M Sell
1,057,707
-80,983
-7% -$3.96M 0.01% 1285
2017
Q3
$57.5M Sell
1,138,690
-51,180
-4% -$2.63M 0.01% 1178
2017
Q2
$64.9M Buy
1,189,870
+101,092
+9% +$4.83M 0.02% 1072
2017
Q1
$45.9M Sell
1,088,778
-123,166
-10% -$5.26M 0.01% 1279
2016
Q4
$52M Buy
1,211,944
+96,188
+9% +$3.91M 0.01% 1244
2016
Q3
$46.1M Sell
1,115,756
-212,504
-16% -$8.9M 0.01% 1267
2016
Q2
$53M Sell
1,328,260
-67,864
-5% -$2.44M 0.02% 1076
2016
Q1
$47M Buy
1,396,124
+117,020
+9% +$3.64M 0.02% 1118
2015
Q4
$43.3M Sell
1,279,104
-73,062
-5% -$2.28M 0.01% 1227
2015
Q3
$40.3M Buy
1,352,166
+1,122,550
+489% +$35.1M 0.01% 1197
2015
Q2
$6.32M Sell
229,616
-1,566,212
-87% -$41.7M ﹤0.01% 2752
2015
Q1
$45.3M Sell
1,795,828
-168,491
-9% -$3.98M 0.01% 1173
2014
Q4
$43.5M Buy
1,964,319
+388,989
+25% +$7.89M 0.01% 1217
2014
Q3
$32M Buy
1,575,330
+596,352
+61% +$11.9M 0.01% 1427
2014
Q2
$18.8M Buy
978,978
+971,093
+12,316% +$18.1M 0.01% 1835
2014
Q1
$148K Sell
7,885
-143,260
-95% -$2.76M ﹤0.01% 6246
2013
Q4
$2.95M Buy
151,145
+77,242
+105% +$1.42M ﹤0.01% 3649
2013
Q3
$1.22M Buy
73,903
+12,670
+21% +$203K ﹤0.01% 4424
2013
Q2
$917K Buy
+61,233
New +$897K ﹤0.01% 4461

Other funds holding IART

Goldman Sachs's IART Position: Q1 2026 in Review

Goldman Sachs increased its Integra LifeSciences (IART) stake by 31% in Q1 2026, buying an estimated $4.84M and bringing the position to 1,876,750 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2554.

Goldman Sachs first reported a position in IART in Q2 2013 and has held it in 52 quarters since. The position peaked at $99.3M in Q4 2021. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • Goldman Sachs held 1,876,750 shares of Integra LifeSciences worth $17.7M as of Q1 2026.
  • Goldman Sachs bought 441,023 Integra LifeSciences shares in Q1 2026, an estimated $4.84M.
  • Integra LifeSciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2554 holding.
  • Goldman Sachs first reported a position in Integra LifeSciences in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Integra LifeSciences position peaked at $99.3M in Q4 2021.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.